AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03247985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProGrip Self-fixating Mesh
Description: ProGrip™ self-fixating mesh is a tack-free fixation mesh for use in open \& laparoscopic hernia repairs. It is composed of absorbable Monofilament Polylactic Acid micro grips on one surface integrated with a lightweight Monofilament Polyethylene Terephthalate. The micro grips act as a kind of Velcro to the soft tissue surfaces resulting in self-fixation
Study NCT01204775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 2.5 mg or 5.0 mg (according to body weight category), Once Daily, 1-52 weeks
Study NCT01204775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saxagliptin)
Description: Tablets, Oral, Once daily, 1-16 weeks
Study NCT04711590 — intervention group
Intervention type: OTHER
Intervention: Microcirculation examination
Description: Sublingual microcirculation images were recorded using an incident dark-field video microscope
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance (dark blue)
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT01854190 — intervention group
Intervention type: DEVICE
Intervention: WatchPAT
Description: BP was measured by oscillometric method on automatic device. Endothelial function was assessed by peripheral arterial tonometry (PAT) by EndoPAT2000® and the OSA diagnosis also through PAT, using the portable device WatchPAT200®. Anthropometric evaluation was performed through measurements of waist, hip and neck circumference, body mass index, waist to height ratio (WHtR), and body composition assessed by bioelectrical impedance.
Study NCT03227289 — intervention group
Intervention type: OTHER
Intervention: Stayed in NRDS
Description: The neonates with NRDS are stayed in NRDS.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance (yellow)
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance (orange)
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance (red)
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unistik 3 Extra
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unistik 3 Comfort
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unistik Touch
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReadyLance (blue)
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReadyLance (orange)
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AssureLance
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AssureLance MicroFlow
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgilance
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgilance Lite (grey)
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgilance Lite (purple)
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SteriLance Lite2
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensiLance (pink)
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SteriLance Press
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensiLance (orange)
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03801733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose of 600 mg QD
Study NCT03801733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Oral Simvastatin
Study NCT03801733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral Rosuvastatin
Study NCT03801733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral Atorvastatin
Study NCT03801733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Oral Pravastatin
Study NCT03801733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Oral Sulfasalazine
Study NCT02260492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT329 (combination of fluticasone propionate and salmeterol xinafoate)
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Solis dry powder inhaler
Study NCT02260492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Diskus dry powder inhaler
Study NCT02260492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (lactose) administered via the Solis dry powder inhaler
Study NCT02402868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine and saline
Description: Ketamine intravenous and intranasal
Study NCT02402868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine and saline
Description: Ketamine intravenous and intranasal
Study NCT01898910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI+renal denervation
Description: After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
Study NCT01898910 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI + GP ablation
Description: To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
Study NCT01898910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medial therapy (OMT)
Description: Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
Study NCT02542124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NM-IL-12 and TSEBT
Description: The LD-TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.
Study NCT02022501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-120
Study NCT03227289 — intervention group
Intervention type: OTHER
Intervention: Converted to ARDS
Description: The neonates with NRDS are converted to ARDS.
Study NCT01063738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acid supplement
Description: Flavoured essential amino acid supplement and glutamine dipeptide taken twice daily for 3 months
Study NCT01063738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEPSE
Description: Enhanced physiotherapy programme of 3 1 hour sessions per week for 6 weeks while in hospital and once discharged home 1 supervised outpatient session of 1 hour and 2 home exercise sessions per week (PEPSE).
Study NCT01063738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Care Unit (ICU) Recovery Manual
Description: Standard self-directed 6 week rehabilitation package
Study NCT01063738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Care Unit (ICU) Recovery Manual
Description: Standard self-directed 6 week rehabilitation package
Study NCT01063738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo nutritional supplement
Description: Cherry flavoured low calorie and low protein placebo drink
Study NCT01063738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo nutritional supplement
Description: Cherry flavoured low calorie and low protein placebo drink
Study NCT02564653 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Technical Assistance, training and clinical reminders
Description: Technical Assistance, training and clinical reminders (TTC)
Study NCT02564653 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TTC+Referral to Community Health Worker
Description: TTC+ referral to a VHW for additional counseling and follow-up
Study NCT02986022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience
Description: Self-efficacy, optimism, altruism, goal setting
Study NCT02986022 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resilience
Description: Self-efficacy, optimism, altruism, goal setting
Study NCT02986022 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: Information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China
Study NCT02897102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Training program based on abacus and other activities
Study NCT02897102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Different group activities
Description: ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants).
Study NCT01275365 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone enanthate
Description: Testosterone enanthate 100 mg intramuscularly weekly
Study NCT05429801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ozone therapy
Description: Rectal ozone treatment along with standard medical treatment was administered to the patients, in increasing doses for 5 sessions per week, 20 sessions in total for 4 weeks. First week: 25 mg/l, 100 ml; second week: 30 mg/l, 150 ml; third week: 35 mg/l, 200 ml; fourth week: 40 mg/l, 200 ml rectal ozone treatment was applied.
Study NCT05429801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Description: Rectal ozone treatment along with standard medical treatment was administered to the patients, in increasing doses for 5 sessions per week, 20 sessions in total for 4 weeks. First week: 25 mg/l, 100 ml; second week: 30 mg/l, 150 ml; third week: 35 mg/l, 200 ml; fourth week: 40 mg/l, 200 ml rectal ozone treatment was applied.
Study NCT02684097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tralokinumab
Description: All groups will receive study drug every two weeks for 24 weeks.
Study NCT02684097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given every two weeks for 24 weeks
Study NCT02464332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLZ-100
Description: All subjects enrolled in the study will receive doses of BLZ-100, an investigational drug for imaging tumors.~Three different imaging windows will be investigated during the study:~Early Imaging (imaging occurs within 1 day post-BLZ-100 dose); Intermediate Imaging (imaging occurs within 2-3 days post-BLZ-100 dose); Late Imaging (imaging occurs 4-7 post-BLZ-100 dose)~All subjects in Part 1 of the study will be imaged in the Intermediate Imaging group. Subjects in Part 2 of the study will be randomized into one of the three imaging groups.
Study NCT01317095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sternalock Rigid Fixation
Description: Patients will have their sternum closed by rigid fixation using Sternalock plates.
Study NCT01839890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bare metal Stent plus Paclitaxel Balloon
Description: After the permeabilization of the clinical event responsible artery with conventional therapy (including the insertion of a conventional metal stent and once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
Study NCT01839890 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare metal Stent
Description: After the permeabilization of the clinical event responsible artery with conventional therapy a conventional metal stent will be inserted. Once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
Study NCT00931528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.
Study NCT00931528 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks.
Study NCT02354677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vitro experiments on bronchial epithelial cells
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mylife
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeriFine
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT03752229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdot
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study NCT00381862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
Study NCT00381862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4
Study NCT00381862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: as per institutional standard of care
Study NCT00381862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: as per institutional standard of care
Study NCT00381862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: as per institutional standard of care
Study NCT00381862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: as per institutional standard of care
Study NCT00381862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron hydrochloride
Description: Palonosetron 0.25 mg IV push on day 1 only.
Study NCT00381862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: baseline
Study NCT03813680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Vertebral Mobilization
Description: Posteroanterior glides was given to cervical spine using Maitland method along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
Study NCT03813680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNF exercise
Description: The subjects was given PNF exercises comprising PNF diagonal patterns for neck along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
Study NCT03813680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Physiotherapy
Description: Thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care